LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 270

Search options

  1. Article: Actualités dans le psoriasis.

    Jullien, D

    Annales de dermatologie et de venereologie

    2019  Volume 146, Issue 12S, Page(s) A7–A8

    Title translation News in psoriasis.
    MeSH term(s) Biosimilar Pharmaceuticals/therapeutic use ; Humans ; Psoriasis/drug therapy ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
    Chemical Substances Biosimilar Pharmaceuticals ; Tumor Necrosis Factor-alpha
    Language French
    Publishing date 2019-10-21
    Publishing country France
    Document type News
    ZDB-ID 391805-1
    ISSN 2214-5451 ; 0151-9638
    ISSN (online) 2214-5451
    ISSN 0151-9638
    DOI 10.1016/j.annder.2019.09.592
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.30: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Effets paradoxaux des biothérapies — Une dénomination erronée ?

    Jullien, D

    Annales de dermatologie et de venereologie

    2018  Volume 145, Issue 6-7, Page(s) 393–394

    Title translation Paradoxical effects of biotherapies - A misnomer?
    MeSH term(s) Biological Therapy/adverse effects ; Humans ; Psoriasis/therapy ; Treatment Outcome
    Language French
    Publishing date 2018-06-01
    Publishing country France
    Document type Editorial
    ZDB-ID 391805-1
    ISSN 2214-5451 ; 0151-9638
    ISSN (online) 2214-5451
    ISSN 0151-9638
    DOI 10.1016/j.annder.2018.04.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.30: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Ustékinumab.

    Jullien, D / Staumont-Salle, D

    Annales de dermatologie et de venereologie

    2019  Volume 146, Issue 6-7, Page(s) 497–502

    Title translation Ustekinumab.
    MeSH term(s) Contraindications, Drug ; Dermatologic Agents/pharmacology ; Female ; Humans ; Interleukin-12/immunology ; Interleukin-23/immunology ; Pregnancy ; Psoriasis/drug therapy ; Ustekinumab/pharmacology ; Vaccines, Attenuated/adverse effects
    Chemical Substances Dermatologic Agents ; Interleukin-23 ; Vaccines, Attenuated ; Interleukin-12 (187348-17-0) ; Ustekinumab (FU77B4U5Z0)
    Language French
    Publishing date 2019-06-14
    Publishing country France
    Document type Journal Article
    ZDB-ID 391805-1
    ISSN 2214-5451 ; 0151-9638
    ISSN (online) 2214-5451
    ISSN 0151-9638
    DOI 10.1016/j.annder.2019.04.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.30: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Chilblain-like lesions after BNT162b2 mRNA COVID-19 vaccine: a case report suggesting that 'COVID toes' are due to the immune reaction to SARS-CoV-2.

    Lesort, C / Kanitakis, J / Donzier, L / Jullien, D

    Journal of the European Academy of Dermatology and Venereology : JEADV

    2021  Volume 35, Issue 10, Page(s) e630–e632

    Language English
    Publishing date 2021-06-30
    Publishing country England
    Document type Letter
    ZDB-ID 1128828-0
    ISSN 1468-3083 ; 0926-9959
    ISSN (online) 1468-3083
    ISSN 0926-9959
    DOI 10.1111/jdv.17451
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3492: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 413: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Physiopathologie du psoriasis.

    Jullien, D

    Annales de dermatologie et de venereologie

    2012  Volume 139 Suppl 2, Page(s) S68–72

    Abstract: Psoriasis is a polymorphous disease. The multiple ways to combine susceptibility genes, immunological mechanisms and modifying factors which interact toward the development of the lesions contribute widely to this polymorphism. It is elusive to look for ... ...

    Title translation Pathogenesis of psoriasis.
    Abstract Psoriasis is a polymorphous disease. The multiple ways to combine susceptibility genes, immunological mechanisms and modifying factors which interact toward the development of the lesions contribute widely to this polymorphism. It is elusive to look for the source of the disease in an exclusive disorder of the immune system or in an isolated primitive change of the epithelial or stromal skin cells. It is more likely that various combinations of selective abnormalities of these two compartments give raise to the psoriatic phenotype. Indeed, if in on hand T-cells are essential in the development of psoriatic plaques, the role of innate immunity in this process is better recognized, and numerous psoriasis susceptibility genes are linked to immunity, on the other hand some susceptibility factors related to primitive abnormalities of keratinocytes and some of the most recent murine models of psoriasis are based on modifications targeted to the keratinocytes. This article makes a current point on the physiopathology of the disease.
    MeSH term(s) Humans ; Psoriasis/etiology ; Psoriasis/genetics ; Psoriasis/immunology ; Psoriasis/physiopathology
    Language French
    Publishing date 2012-04
    Publishing country France
    Document type English Abstract ; Journal Article
    ZDB-ID 391805-1
    ISSN 2214-5451 ; 0151-9638
    ISSN (online) 2214-5451
    ISSN 0151-9638
    DOI 10.1016/S0151-9638(12)70113-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.30: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Anticorps anti-médicament, auto-anticorps et traitements biologiques du psoriasis.

    Jullien, D

    Annales de dermatologie et de venereologie

    2012  Volume 139 Suppl 2, Page(s) S58–67

    Abstract: The approval of substantial numbers of targeted biologic therapies (e.g., monoclonal antibodies, fusion proteins) for treatment of inflammatory diseases has positioned these drugs as important to fight chronic disorders such as psoriasis, rheumatoid ... ...

    Title translation Anti-drug antibodies, auto-antibodies and biotherapy in psoriasis.
    Abstract The approval of substantial numbers of targeted biologic therapies (e.g., monoclonal antibodies, fusion proteins) for treatment of inflammatory diseases has positioned these drugs as important to fight chronic disorders such as psoriasis, rheumatoid arthritis and Crohn's disease. One of the concerns raised with the administration of biologic therapies is that because most of them are immunogenic glycoproteins they induce undesirable immune response leading to the generation of specific anti-drug antibodies (ADA). The development of "self" derived protein therapeutics (comprised of human germline sequence), such as recombinant "human" antibodies, helped to reduce the production of ADA but did not avoid all immunogenicity. Reduced efficacy and safety issues such as anaphylaxis or vasculitis accompany the development of ADA. In addition to immune reactions directed against the biologic therapies as a whole, some of them such as anti-TNFα are able to induce auto-immune response, notably antinuclear antibody (ANA). ANA development was associated with induced lupus and in psoriasis it was suggested that it may act as a marker of treatment failure to anti-TNFα. With a focus on psoriasis, this paper makes a current point on the consequences and challenges of the development of anti-drug antibodies and auto-immunity in patients who receive biologic therapies.
    MeSH term(s) Antibody Formation ; Autoantibodies/biosynthesis ; Drug Resistance/immunology ; Humans ; Immunotherapy ; Psoriasis/drug therapy ; Psoriasis/immunology ; Psoriasis/therapy
    Chemical Substances Autoantibodies
    Language French
    Publishing date 2012-04
    Publishing country France
    Document type English Abstract ; Journal Article
    ZDB-ID 391805-1
    ISSN 2214-5451 ; 0151-9638
    ISSN (online) 2214-5451
    ISSN 0151-9638
    DOI 10.1016/S0151-9638(12)70112-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.30: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Real-world evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies.

    Augustin, M / Jullien, D / Martin, A / Peralta, C

    Journal of the European Academy of Dermatology and Venereology : JEADV

    2020  Volume 34, Issue 6, Page(s) 1174–1185

    Abstract: Real-world evidence (RWE) meta-analyses provide valuable insights from patients in routine clinical practice. Secukinumab, the first fully human monoclonal antibody that neutralizes IL-17A, has shown long-lasting effectiveness and safety in plaque ... ...

    Abstract Real-world evidence (RWE) meta-analyses provide valuable insights from patients in routine clinical practice. Secukinumab, the first fully human monoclonal antibody that neutralizes IL-17A, has shown long-lasting effectiveness and safety in plaque psoriasis (PsO). Since its licence approval in 2015, many RWE studies have been published. The objective of this study was to review all available literature on RWE studies with secukinumab and the secukinumab arm of comparator studies in patients with moderate-to-severe PsO to evaluate its effectiveness, drug survival and safety. https://www.embase.com and https://clinicaltrials.gov databases were searched using prespecified inclusion criteria between 1 January 2015 and 31 May 2019. Using a meta-package and R statistical software to analyse data, key outcomes were measured at 3, 6 and 12 months. PASI and DLQI score data were recorded for patients who remained on secukinumab treatment. Overall, 43 studies were included. Drug survival was 90% at 3 and 6 months, and 80% at 12 months. At 12 months, 8% of patients had discontinued treatment due to lack of effectiveness. At 3, 6 and 12 months, Psoriasis Area and Severity Index (PASI) 90 scores were as follows: 50%, 53% and 60%, and PASI 100 scores were 36%, 46% and 51%, respectively. At 3, 6 and 12 months, 57%, 55% and 65% of patients achieved a Dermatology Life Quality Index (DLQI) score of 0 or 1, respectively. Adverse events were consistent with rates observed in clinical trials with no new safety signals. This meta-analysis strengthens existing evidence on the clinical effectiveness of secukinumab in patients with moderate-to-severe PsO, demonstrating high drug survival rates, high levels of patient-reported outcomes, and good tolerance.
    MeSH term(s) Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Humans ; Psoriasis/drug therapy ; Severity of Illness Index ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; secukinumab (DLG4EML025)
    Language English
    Publishing date 2020-02-18
    Publishing country England
    Document type Journal Article ; Meta-Analysis ; Review
    ZDB-ID 1128828-0
    ISSN 1468-3083 ; 0926-9959
    ISSN (online) 1468-3083
    ISSN 0926-9959
    DOI 10.1111/jdv.16180
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3492: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 413: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Realization of an advanced super-mirror solid-state neutron polarizer for the instrument PF1B at the Institut Laue-Langevin.

    Petoukhov, A K / Nesvizhevsky, V V / Bigault, T / Courtois, P / Devishvili, A / Jullien, D / Soldner, T

    The Review of scientific instruments

    2023  Volume 94, Issue 2, Page(s) 23304

    Abstract: In this last of a series of three papers on the development of an advanced solid-state neutron polarizer, we present the final construction of the polarizer and the results of its commissioning. The polarizer uses spin-selective reflection of neutrons by ...

    Abstract In this last of a series of three papers on the development of an advanced solid-state neutron polarizer, we present the final construction of the polarizer and the results of its commissioning. The polarizer uses spin-selective reflection of neutrons by interfaces coated with polarizing super-mirrors. The polarizer is built entirely in-house for the PF1B cold neutron beam facility at the Institut Max von Laue-Paul Langevin (ILL). It has been installed in the PF1B casemate and tested under real conditions. The average transmission for the "good" spin component is measured to be >30%. The polarization averaged over the capture spectrum reaches a record value of P
    Language English
    Publishing date 2023-03-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 209865-9
    ISSN 1089-7623 ; 0034-6748
    ISSN (online) 1089-7623
    ISSN 0034-6748
    DOI 10.1063/5.0123419
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Bonn / Germany

    Z 4' 46/112: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article ; Online: Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest.

    Egeberg, Alexander / Jullien, Denis / Gaarn Du Jardin, Kristian / Thaçi, Diamant

    The Journal of dermatological treatment

    2023  Volume 34, Issue 1, Page(s) 2220447

    Abstract: Background: Five-year tildrakizumab safety data have been reported as exposure-adjusted incidence rates (EAIRs) of patients with events per 100 patient-years (PYs) of exposure.: Objectives: To present 5-year safety data from reSURFACE 1/2 phase 3 ... ...

    Abstract Background: Five-year tildrakizumab safety data have been reported as exposure-adjusted incidence rates (EAIRs) of patients with events per 100 patient-years (PYs) of exposure.
    Objectives: To present 5-year safety data from reSURFACE 1/2 phase 3 trials as EAIRs of events per 100 PYs of exposure, and the number needed to harm (NNH) for one adverse event of special interest (AESI) to occur.
    Methods: Pooled analysis from two randomized controlled trials in patients with moderate-to-severe plaque psoriasis (
    Results: Rates of AESI with tildrakizumab were comparable with rates reported in PSOLAR. The NNH for one-year severe infection occurrence was 412 with tildrakizumab 200 mg, and negative for tildrakizumab 100 mg due to lower rates in reSURFACE trials; the NNH for malignancy was 990 for one year with tildrakizumab 100 mg (negative for tildrakizumab 200 mg); and the NNH for major adverse cardiovascular events was 355 for one year with tildrakizumab 200 mg (negative for tildrakizumab 100 mg).
    Conclusion: Tildrakizumab demonstrated a favorable safety profile over 5 years with low rates of AESI, comparable to those of the PSOLAR. Consequently, the NNH for AESI with tildrakizumab were very high or negative due to lower event rates for tildrakizumab.
    MeSH term(s) Humans ; Antibodies, Monoclonal, Humanized/adverse effects ; Patients ; Psoriasis/drug therapy ; Registries
    Chemical Substances tildrakizumab (DEW6X41BEK) ; Antibodies, Monoclonal, Humanized
    Language English
    Publishing date 2023-06-19
    Publishing country England
    Document type Clinical Trial, Phase III ; Journal Article
    ZDB-ID 1036299-x
    ISSN 1471-1753 ; 0954-6634
    ISSN (online) 1471-1753
    ISSN 0954-6634
    DOI 10.1080/09546634.2023.2220447
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2627: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: The usefulness of omalizumab in low response to corticosteroids DRESS syndrome: A case series.

    Ben Said, Benoit / Dupire, Gwendy / Poutrel, Solene / Jullien, Denis

    The journal of allergy and clinical immunology. In practice

    2023  Volume 12, Issue 1, Page(s) 236–238

    MeSH term(s) Humans ; Drug Hypersensitivity Syndrome/diagnosis ; Drug Hypersensitivity Syndrome/drug therapy ; Omalizumab/therapeutic use ; Adrenal Cortex Hormones/therapeutic use ; Anticonvulsants
    Chemical Substances Omalizumab (2P471X1Z11) ; Adrenal Cortex Hormones ; Anticonvulsants
    Language English
    Publishing date 2023-10-05
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2843237-X
    ISSN 2213-2201 ; 2213-2198
    ISSN (online) 2213-2201
    ISSN 2213-2198
    DOI 10.1016/j.jaip.2023.09.036
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7086: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top